Old Web
English
Sign In
Acemap
>
Paper
>
IREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 spinal muscular atrophy (SMA)
IREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 spinal muscular atrophy (SMA)
2021
Riccardo Masson
Odile Boespflug-Tanguy
Basil T. Darras
J. Day
Nicolas Deconinck
Andrea Klein
Maria Mazurkiewicz-Bełdzińska
Eugenio Mercuri
Kristy Rose
L. Servais
D. Vlodavets
H. Xiong
Edmar Zanoteli
A Dodman
M. El-Khairi
E. Gaki
Marianne Gerber
Ksenija Gorni
Heidemarie Kletzl
Giovanni Baranello
Keywords:
Pathology
SMA*
Spinal muscular atrophy
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]